Successful eculizumab treatment as an adjunctive therapy to desensitization in ABO-incompatible living donor kidney transplantation and its molecular phenotypes.

MLA

Heo, Ga Young, et al. “Successful Eculizumab Treatment as an Adjunctive Therapy to Desensitization in ABO-Incompatible Living Donor Kidney Transplantation and Its Molecular Phenotypes.” Frontiers in Immunology, vol. 15, Oct. 2024, p. 1465851. EBSCOhost, https://doi.org/10.3389/fimmu.2024.1465851.

APA

Heo, G. Y., Jung, M., Piao, H., Kim, H. J., Kim, H. W., Lee, J., Huh, K. H., Kim, B. S., & Yang, J. (2024). Successful eculizumab treatment as an adjunctive therapy to desensitization in ABO-incompatible living donor kidney transplantation and its molecular phenotypes. Frontiers in Immunology, 15, 1465851. https://doi.org/10.3389/fimmu.2024.1465851

Chicago

Heo, Ga Young, Minsun Jung, Honglin Piao, Hyun Jeong Kim, Hyung Woo Kim, Juhan Lee, Kyu Ha Huh, Beom Seok Kim, and Jaeseok Yang. 2024. “Successful Eculizumab Treatment as an Adjunctive Therapy to Desensitization in ABO-Incompatible Living Donor Kidney Transplantation and Its Molecular Phenotypes.” Frontiers in Immunology 15 (October): 1465851. doi:10.3389/fimmu.2024.1465851.